Fluorocyclopentenylcytosine - Rexahn Pharmaceuticals

Drug Profile

Fluorocyclopentenylcytosine - Rexahn Pharmaceuticals

Alternative Names: FCPEC; RX 3117

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Oct 2018 Preliminary efficacy and adverse events data from a phase IIa trial in Pancreatic cancer released by Rexahn Pharmaceuticals
  • 04 Jun 2018 Interim efficacy and safety data from a phase IIa trial in Bladder cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 12 Feb 2018 Interim efficacy data from a phase II trial in Bladder cancer released by Rexahn Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top